Detalles de la búsqueda
1.
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1).
Br J Cancer
; 130(3): 434-441, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38102226
2.
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide.
Prostate
; 83(4): 376-384, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36564933
3.
Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
BMC Cancer
; 19(1): 766, 2019 Aug 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31382926
4.
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
Lancet Oncol
; 18(5): 672-681a, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28389316
5.
Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study.
BMC Cancer
; 16: 135, 2016 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26906039
6.
SEOM SOGUG clinical guideline for treatment of kidney cancer (2022).
Clin Transl Oncol
; 25(9): 2732-2748, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37556095
7.
Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16).
J Clin Oncol
; 41(20): 3608-3615, 2023 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36753698
8.
Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer.
Clin Transl Oncol
; 25(4): 897-911, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36525230
9.
Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancer.
Clin Transl Oncol
; 25(4): 882-896, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36525231
10.
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study.
Eur Urol Oncol
; 2023 Oct 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37838555
11.
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Lancet Oncol
; 12(12): 1143-50, 2011 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-22015057
12.
Bone loss induced by cancer treatments in breast and prostate cancer patients.
Clin Transl Oncol
; 24(11): 2090-2106, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35779210
13.
Management of Patients with Metastatic Bladder Cancer in the Real-World Setting from the Multidisciplinary Team: Current Opinion of the SOGUG Multidisciplinary Working Group.
Cancers (Basel)
; 14(5)2022 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35267437
14.
SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021).
Clin Transl Oncol
; 24(4): 613-624, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35347572
15.
Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors.
Front Cardiovasc Med
; 9: 1062858, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36531707
16.
Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group.
Clin Genitourin Cancer
; 20(4): 388.e1-388.e10, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35428584
17.
Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain.
Clin Transl Oncol
; 24(3): 495-502, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34482526
18.
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial.
Eur J Cancer
; 173: 317-326, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35981452
19.
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial.
Eur J Cancer
; 175: 110-119, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36099670
20.
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study.
Clin Genitourin Cancer
; 20(1): 25-34, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34789409